North Ryde, Australia Clinical Trials

A listing of North Ryde, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. PURPOSE: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer.

orchiectomy
androgens
antiandrogens
androgen suppression
antiandrogen therapy
Sydney Cancer Centre at Royal Prince Alfred Hospital
 (7.5 away) Contact site
  • 401 views
  • 07 Nov, 2020
  • +8 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Northern Cancer Insitute, St. Leonards
 (4.8 away) Contact site
  • 2496 views
  • 21 Sep, 2020
  • +209 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Macquarie University Hospital
 (1.3 away) Contact site
  • 0 views
  • 23 Nov, 2020
  • +348 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with …

Chris OBrien Lifehouse ( Site 0300)
 (7.3 away) Contact site
  • 272 views
  • 05 Dec, 2020
  • +184 other locations
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants with mCRPC who have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy. …

MRI
castration-resistant prostate cancer
serum testosterone
diphosphonates
bisphosphonate
Macquarie University ( Site 0151)
 (1.3 away) Contact site
  • 394 views
  • 04 Dec, 2020
  • +202 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

fitusiran
antihemophilic factor
severe haemophilia a
hemarthrosis
Investigational Site Number 0360001
 (7.3 away) Contact site
  • 180 views
  • 03 Dec, 2020
  • +65 other locations
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC but have progressed on or are intolerant to Next Generation Hormonal Agent …

MRI
castration-resistant prostate cancer
serum testosterone
diphosphonates
bisphosphonate
Macquarie University ( Site 0151)
 (1.3 away) Contact site
  • 296 views
  • 04 Dec, 2020
  • +212 other locations
A Study of Apalutamide in Participants With High-Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to placebo …

androgens
prostatectomy
adenocarcinoma
metastasis
adenocarcinoma of prostate
Northern Cancer Institute
 (4.8 away) Contact site
  • 291 views
  • 22 Nov, 2020
  • +349 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP plus placebo.

Macquarie University
 (1.3 away) Contact site
  • 498 views
  • 15 Oct, 2020
  • +479 other locations
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (< 50 nanograms/deciliter [ng/dL]) in participants with androgen-sensitive advanced prostate cancer.

testosterone
androgens
prostatectomy
adenocarcinoma
serum testosterone
Wahroonga
 (5.1 away) Contact site
  • 1590 views
  • 04 Nov, 2020
  • +351 other locations